Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jan;6(1):4-10.
doi: 10.1631/jzus.2005.B0004.

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Jian Liu, Shu Zheng, Jie-kai Yu, Jian-min Zhang, Zhe Chen
Clinical Trial

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Jian Liu et al. J Zhejiang Univ Sci B. 2005 Jan.

Abstract

To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm. SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals. Two thirds of the total samples of every compared pair as training set were used to set up discriminating patterns, and one third of total samples of every compared pair as test set were used to cross-validate; simultaneously, discriminate-cluster analysis derived SPSS 10.0 software was used to compare Astrocytoma grade I-II with grade III-IV ones. An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor. Total accuracy of 85.7%, accuracy of grade I-II Astrocytoma was 86.7%, accuracy of III-IV Astrocytoma was 84.6% were obtained when grade I-II Astrocytoma was compared with grade III-IV ones (discriminant analysis). SELDI-TOF-MS combined with bioinformatics tools, could greatly facilitate the discovery of better biomarkers. The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative spectra and gel views of the selected biomarkers of Astrocytoma patients and healthy individuals. (a) The biomarker of 8214.8 m/z; (b) The biomarker of 2368.2 m/z
Fig. 1
Fig. 1
Representative spectra and gel views of the selected biomarkers of Astrocytoma patients and healthy individuals. (a) The biomarker of 8214.8 m/z; (b) The biomarker of 2368.2 m/z
Fig. 2
Fig. 2
Distribution of the cases of test set across the couple of Astrocytoma patients and healthy individuals by the selected biomarkers of fifteen peaks (8214.77 m/z, 8926.76 m/z, 4815.11 m/z, 8612.23 m/z, 2082.19 m/z, 4299.87 m/z, 2103.55 m/z, 7764.82 m/z, 2368.19 m/z, 3226.97 m/z, 2389.55 m/z, 2021.78 m/z, 4469.09 m/z, 6457.054 m/z, 8702.416 m/z). When predictive value>0.5, the cases were judged as Astrocytoma; when predictive value≤0.5, the cases were judged as healthy individuals. In the figure, only one case of Astrocytoma was misjudged, and the rest were all judged correctly
Fig. 3
Fig. 3
Representative spectra and gel views of the selected biomarkers of Astrocytoma and benign brain tumor. (a) The biomarker of 4155.3 m/z; (b) The biomarker of 14047.8 m/z
Fig. 3
Fig. 3
Representative spectra and gel views of the selected biomarkers of Astrocytoma and benign brain tumor. (a) The biomarker of 4155.3 m/z; (b) The biomarker of 14047.8 m/z
Fig. 4
Fig. 4
Distribution of the cases of test set across the couple of Astrocytoma and brain benign tumor by the selected biomarkers of 22 peaks (2256.76 m/z, 23481.05 m/z, 9198.31 m/z, 22513.91 m/z, 22888.73 m/z, 23087.61 m/z, 4155.28 m/z, 2489.11 m/z, 2246.47 m/z, 2617.14 m/z, 15099.38 m/z, 22666.41 m/z, 29047.13 m/z, 14378.33 m/z, 24002.85 m/z, 2891.43 m/z, 14047.77 m/z, 2006.00 m/z, 14951.04 m/z, 2267.22 m/z, 23672.58 m/z, 22331.29 m/z). When predictive value>0.5, the cases were judged as Astrocytoma; when predictive value≤0.5, the cases were judged as brain benign tumor. In the figure, one case of Astrocytoma and two cases of brain benign tumor were misjudged, and the rest of the cases were all judged correctly
See this image and copyright information in PMC

References

    1. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, Mccardle S, ElLis IQ, Creaser C, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics. 2002;18(3):395–404. - PubMed
    1. Bast RCJr. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21(10 Suppl):200–205. - PubMed
    1. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GLJ. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by Surface Enhanced Laser Desorption/Ionization mass spectrometry. Clin Cancer Res. 2002;8(8):2541–2552. - PubMed
    1. DeAngelis LM. Brain tumors. New England J Medicine. 2001;344(2):114–123. - PubMed
    1. Jemal A, Murray T, Samuels A, Chafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer JCLIN. 2003;53(1):5–26. - PubMed

MeSH terms